Pfizer Inc. $PFE Stock Holdings Boosted by Plan Group Financial LLC

Plan Group Financial LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 17.6% during the second quarter, Holdings Channel reports. The institutional investor owned 133,266 shares of the biopharmaceutical company’s stock after buying an additional 19,918 shares during the quarter. Plan Group Financial LLC’s holdings in Pfizer were worth $3,209,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Vermillion Wealth Management Inc. raised its position in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares in the last quarter. Eagle Capital Management LLC grew its stake in shares of Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the last quarter. Delta Financial Advisors LLC raised its holdings in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 398 shares in the last quarter. Pines Wealth Management LLC boosted its holdings in Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 400 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD grew its position in Pfizer by 1.0% in the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 400 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. dropped their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Guggenheim dropped their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.28.

Pfizer Stock Up 0.3%

Pfizer stock opened at $26.88 on Tuesday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market cap of $153.21 billion, a PE ratio of 35.37 and a beta of 0.34. The firm’s 50 day moving average price is $25.15 and its two-hundred day moving average price is $26.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the company posted $0.78 EPS. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.